SERPINA1 and hyperinsulinemic hypoglycemia, familial, 4: In recent years, gene therapy has emerged as a promising option for treating various liver disorders.[62] For example, in clinical trials, the treatment of α1‐antitrypsin deficiency was achieved through the injection of siRNA or antisense oligonucleotides, aimed at reducing the expression of the mutated SERPINA1 gene in hepatocytes and minimizing the accumulation of toxic protein.[63] Currently, there are no clinical trials of gene therapy for inhibiting EV secretion.